Mealey's (December 3, 2020, 1:18 PM EST) -- TRENTON, N.J. — In a Nov. 30 complaint filed in the U.S. District Court for the District of New Jersey, the makers of VASCEPA — a brand name prescription medication that reduces the risk of cardiovascular (CV) events — assert that efforts to market a generic bioequivalent would infringe three patents (Amarin Pharma Inc., et al. v. Hikma Pharmaceuticals PLC, et al., No. 20-1630, D. N.J.)....